Seer EBITDA Margin 2020-2022 | SEER

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Seer (SEER) over the last 10 years. The current EBITDA margin for Seer as of March 31, 2022 is .
Seer EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2022-03-31 $0.01B $-0.08B -833.33%
2021-12-31 $0.01B $-0.07B -1133.33%
2021-09-30 $0.00B $-0.06B -2033.33%
2021-06-30 $0.00B $-0.05B -5200.00%
2021-03-31 $0.00B $-0.04B inf%
2020-12-31 $0.00B $-0.03B inf%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.613B $0.007B
Seer Inc. is a life sciences company. It engages in developing Proteograph(TM), which is an integrated solution consisting of consumables, automation instrumentation and proprietary software. Seer Inc. is based in REDWOOD CITY, Calif.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00